Thanks, bobad, for citing a reliable source abstract (Proceedings of the National Academy of Sciences). The 44 contributing authors show the cooperation of researchers from many different institutions (some are commercial, it should be noted.
Tests will take several years, but the use of the immune system is most promising.

Attached to the abstract is a conflict of interest statement; some institutions have applied to patent aspects of the approach. If allowed, that could add to cost of the treatments once they have been tested and applied.

"Drug Institutions" are not interested in keeping things the way they are. New drugs are being developed constantly by these companies, they have many new ones that may or may not have value, and they are offered to researchers who might wish to test them in their programs.
Their propriatary approach to add profit from new methods may seem deplorable, but it is a part of the economic system that we have evolved.


But this is not simply a new drug, it goes far beyond that.